Drug intelligence / Profile preview

PNV-002

Development stage: Preclinical
Lead developer: ProNovo Therapeutics

Overview

PNV-002 is a preclinical-stage drug candidate being developed by ProNovo Therapeutics for the treatment of schizophrenia. The company describes the asset as an "emerging mechanism-based, best-in-class" opportunity, suggesting a novel or optimized approach to the biological drivers of the disorder. As of early 2025, the program is in the preclinical phase of development, supported by seed financing intended to advance ProNovo's neuropsychiatric pipeline. Specific details regarding its molecular target and modality remain proprietary and have not been publicly disclosed.

Beyond the preview

Go deeper on PNV-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNV-002.

Explore the full profile